Phase 2 N=58 Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
Insomnia Disorder
Primary: Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2 — -18.9; -32.0; -45.1; -61.4 minutes — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain
Diabetes
Primary: Reporting of Adverse Events During 12 Week Study Period — 9; 8; 7; 29 Adverse Events
Phase 2 N=38 Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
Glioma
Primary: Number of Patients Who Had 6-month Progression-free Survival. — 3 Participants
Phase 2 N=30 The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
Chronic Rhinitis
Primary: Change in Subjective Nasal Scoring — 0.62; 1.53 score on a scale — p=0.013
Phase 2 N=55 Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Lung Cancer
Primary: Dose-limiting Toxicity — 0 Dose-limiting toxicities
Phase 2 N=65 A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Crohn Disease
Primary: Number of Participants With Adverse Events — 2; 60; 60 Participants
Phase 2 N=60 A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Lymphoma
Primary: Objective Response Rate Based on Lugano Classification Criteria in Group A — 25.5 percentage
Phase 2 N=7 Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
Lower Urinary Tract Symptoms
Primary: Lactobacillus Safety — .286 Adverse Events — p==0.351
Phase 2 N=532 Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in Weekly Abdominal Pain Score Over the 12-Week Treatment Period: DR1 or IR vs. Placebo — -1.370; -1.938; -1.667; -1.656 score on a scale — p=0.0839
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
Phase 2 N=40 Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Hepatocellular Cancer
Primary: Time to Progression — 7.7 Months
Phase 2 N=71 Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL
Phase 2 N=45 PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
Lymphoma, Diffuse Large B-Cell
Primary: Overall Response Rate — 11.1 percentage of participants
Phase 2 N=13 High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders
Very Long-chain Acyl-CoA Dehydrogenase Deficiency · Trifunctional Protein Deficiency · Carnitine Palmitoyltransferase 2 Deficiency
Primary: Energy Expenditure — 2045; 2343 kcal
Phase 2 N=57 Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope
Vasovagal Syncope
Primary: Number of Participants Who Become Syncopal Associated With Diagnostic Criteria of Hypotension and Bradycardia — 19; 10 Participants